Generic Name: Danaparoid sodium
Product Name: Orgaran
Orgaran is used to prevent post operative deep vein thrombosis, (DVT), that is, the formation and break up of blood clots in the leg veins of patients after surgery.
Orgaran (Danaparoid) works to prevent blood clots forming by stopping the final step in the process of clot formation. Although Orgaran acts to stop clot formation, it does not greatly increase the risk of bleeding.
Maximum Orgaran levels are reached in the body in 4-5 hours. Orgaran is excreted by the kidneys. It has a half life of 25 hours.
Orgaran is given twice daily, by subcutaneous injection.
- It is recommended to give the last dose 1-4 hours before surgery.
Patients with severely impaired renal function
- Orgaran doses may have to be reduced.
- Clearance is not markedly reduced, and usual dosage is recommended.
Common side effects
- Bruising and/or pain may occur at injection sites.
- Increased bleeding
Uncommon side effects
- Skin rashes and other local or generalised hypersensitivity reactions have occurred.
- Orgaran could theoretically induce thrombocytopenia, however this has yet to be observed. Platelet levels should be monitored regularly during therapy.
- Changes in liver enzyme levels have been recorded, however the clinical significance of this has not been determined.
For further information talk to your doctor.